CD38 and Miyoshi myopathy: In fact, the anti-CD38 mAb Daratumumab has been included as first-line therapy in both transplant eligible and ineligible MM patients, with several other mAb and antibody–drug conjugates (ADC) being approved for refractory patients or being tested in clinical trials (Table 1) [5,6,7].